L eft ventricular assist devices (LVAD) are increasingly becoming an accepted treatment option for medically refractory advanced heart failure patients who are nontransplant eligible. [1] [2] [3] The prospective, randomized clinical trial comparing the HeartMate II (HMII) and the HeartMate XVE LVADs demonstrated a significant improvement in survival and an overall reduction in adverse events for the HMII. 2, 3 Significant improvements in quality of life and functional status have also been reported during LVAD support. 4 The results of the clinical trial led to the Food and Drug Administration (FDA) approval of the HMII as destination therapy (DT). The approval of HMII as both bridge to transplantation (BTT) in April 2008 and DT in January 2010 has now made mechanical circulatory support therapy available to a wider group of patients. More than 6000 patients have been supported by the HMII either as BTT or DT from 2004 through 2010, with nearly 3000 US patients receiving the device after FDA approval, whose data have already reported in the national INTERMACS registry. 5 
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However, new surgical advances do have a learning curve, and improvements in outcomes with increasing clinical experience should be expected. This has been previously evident in the HMII BTT experience, in which 1-year survival increased from 68% reported in the original cohort of patients enrolled from March 2005 to May 2006 6 to 73% in the midtrial update, 7 to 85% in the postapproval study representing the first cohort of patients supported by this device in a commercial setting. 8 Furthermore, recent publications from single center publications have reported similar outcomes in a diverse group of patients. 9 -12 For example, Adamson et al 10 outlined clinical strategies and approaches that may help toward achieving good outcomes in elderly patients, in which they reported a 2-year survival of 70% in patients older than 70 years receiving an LVAD. Other studies have investigated HMII in restrictive and hypertrophic cardiomyopathies, 9 relationship between the acuity of heart failure with improved survival and length of stay, 11 as well as reversal of heart failure that can be achieved with an LVAD in combination with pharmacological therapy. 12 Patients in the original DT trial were enrolled at the same time as those in the initial BTT cohort but had a longer follow-up than the BTT patients. Since results of the first 133 HMII DT patients were published, 2 an additional 600 patients have been enrolled into the clinical trial as part of a continued access protocol. The goal of this report is to compare outcomes in patients enrolled later in the trial under continued access protocol with outcomes of the initial primary patient cohort. The main hypothesis is that patients implanted in the later part of the trial would have better clinical outcomes compared with those who were implanted earlier.
Methods
This study is a retrospective analysis of patients enrolled in the multicenter HMII DT trial who were followed up for at least 2 years after HMII LVAD implantation. Only patients who received the HMII device for DT were included. Patients who received the HeartMate XVE in the randomized part of the trial or received a HMII as an exchange for a HeartMate XVE were excluded from the analysis. The clinical trial was supervised and monitored by Thoratec Corporation. A data and safety monitoring board, consisting of 4 independent physicians and 1 biostatistician who were not investigators, met regularly to review study compliance, adverse events, quality of life, and outcomes. The study was conducted in compliance with FDA regulations for Good Clinical Practices. The protocol was approved by the FDA and the institutional review board at each participating center. The academic authors vouch for the completeness and accuracy of the data.
Study Subjects
Details on the study inclusion and exclusion criteria for the DT trial are published elsewhere. 2 Patients with advanced heart failure who were ineligible for heart transplantation and were refractory to optimal medical management were considered for enrollment. Enrolled patients met the following criteria: ejection fraction of Ͻ25%, peak VO 2 Ͻ14 mL/kg per minute or Ͻ50% of the predicted value, New York Heart Association (NYHA) class IIIB or IV symptoms for at least 45 of the 60 days, or dependence on an intra-aortic balloon pump (IABP) for 7 days or inotropes for a period of at least 14 days before enrollment. Patients were excluded for severe renal (serum creatinine Ͼ3.5 mg/dL or long-term dialysis), hepatic (international normalized ratio [INR] Ͼ2.5, total bilirubin Ͼ5 mg/dL, or transaminases Ͼ2000 U/L), or pulmonary (severe chronic obstructive pulmonary disease) dysfunction. Patients with uncontrolled infections, previous strokes, mechanical aortic valves, irreparable aortic insufficiency, aortic aneurysm Ͼ5.0 cm, or other mechanical circulatory support devices (except IABPs) also were excluded. Enrolled subjects with clinical follow-up data for at least 2 years after implant were included in this subanalysis.
Patients were divided into 2 groups: (1) the Early Trial group, comprising the initial 133 patients implanted with a HMII who were 
Data Collection Baseline Assessment
Data analyzed included patient characteristics and demographics (age, sex, heart failure etiology, NYHA class, history of prior stroke, body surface area, weight), baseline hemodynamics (left ventricular ejection fraction, cardiac index, central venous pressure, pulmonary capillary wedge pressure, pulmonary vascular resistance, pulmonary artery pressure, and systemic blood pressure), laboratory values (creatinine, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, total bilirubin, and serum sodium), and baseline device/medical therapy (cardiac resynchronization therapy, implantable cardioverter-defibrillator, ventilator support, IABP, angiotensinconverting enzyme inhibitors, ␤-blockers, and inotropes). In addition, the model for end-stage liver disease (MELD) and destination therapy risk score (DTRS) 13 were calculated for each patient at implantation.
Follow-Up After Device Implantation
Postoperative medical care (including inotropic, antiarrhythmic, anticoagulant, and heart failure therapy) was managed according to each investigator's preference and usual practice. Device performance, laboratory results, and medication use were initially recorded at daily to weekly intervals until hospital discharge and then were recorded monthly. All deaths of patients and causes of death were determined at autopsy when possible or by examination of medical records or by interviews with family members. Final adjudication was determined by the clinical events committee.
Outcomes
Kaplan-Meier survival was evaluated and compared for both the patient groups. Survival free from disabling stroke and reoperation to repair or replace the LVAD at 2 years was evaluated and was compared between the Early and Mid Trial patient groups using as-treated analysis. Other secondary outcomes comprised of functional capacity, quality of life, and adverse events. Functional assessments and quality-of-life questionnaires were obtained at baseline when possible before LVAD implantation and at months 1, 3, 6, 12, 18, and 24 months. Functional status measurements included independently assessed NYHA functional class, and 6-minute walk distances. Heart failure-related quality of life was assessed by using responses from the Minnesota Living with Heart Failure (MLWHF) and the Kansas City Cardiomyopathy questionnaires (KCCQ). Adverse events were recorded throughout the study until the analysis cutoff date with the use of standardized definitions (see the supplementary appendix of Slaughter et al 2 ).
Statistical Analysis
Differences between groups of independent, normally distributed, continuous variables were evaluated using the t test. Variables that were not normally distributed were evaluated using the nonparametric Mann-Whitney U test. Differences in categorical variables were evaluated using the Fisher exact test or Pearson 2 test for more than 2 groups. Survival analysis was performed using the Kaplan-Meier method with patients censored for ongoing device support, transplantation, recovery of the native heart function with device removal, or withdrawal from the study. Comparison of survival between the 2 groups was performed using the log-rank test. Adverse events are presented as both percentages of patients and event rates (events per patient year). Risk ratio evaluation and comparison of adverse event rates between the 2 groups were performed using Cochran-Mantel-Haenszel statistics. Adverse events in the Mid Trial group were 
Results

Baseline Characteristics
Baseline parameters were characteristic of extremely ill patients with advanced heart failure. Patients in the Mid Trial group were similar for all parameters except for slightly smaller body surface area and weight (Table 1) . Predicted 1-year survival rates, if patients had remained on medical treatment, were not significantly different between the groups and were Ͻ50% for both groups using the Seattle Heart Failure Model. 14 
Outcomes
Median duration of support was 1.7 years (range, 0.0 -6) for the Mid Trial group and 2.1 years (range, 0.0 -4) for the Early Trial group, with a cumulative follow-up duration of 280 and 498 patient-years, respectively. Kaplan-Meier survival curves (Figure 1 ) at 12 and 24 months for the Mid Trial group were 73Ϯ3% and 63Ϯ3%, compared with the Early Trial experience of 68Ϯ4% and 58Ϯ4% (Pϭ0.209 log-rank test). The percentage of patients reaching the end point of survival free from disabling stroke and reoperation to replace the device at 2 years in the Mid Trial group was 59% [166/281], compared with 50% in the Early Trial group [66/133] (Pϭ0.073). There was trend of reduction in disabling stroke at 2 years at 6% [17/281] 
Functional Assessment and Quality of Life
Early and sustained improvements in quality of life were seen in both groups, and there was a trend toward patients having a better quality of life in the Mid Trial group compared with Early Trial (Figure 2 ). KCCQ overall summary score were similar at baseline at 28Ϯ18 (Mid Trial) and 27Ϯ16 (Early Trial) and showed improvement in both groups by 6 months at 70Ϯ21 in the Mid Trial group, which was slightly greater than 64Ϯ20 for the Early Trial group. There were sustained improvements in both groups for 24 months, with a trend for KCCQ scores to be higher in the Mid Trial group compared with the early trial group (Pϭ0.080). MLWHF total score showed similar improvements for both groups, with significantly better scores seen in the Mid Trial compared with Early Trial groups (Pϭ0.043). 
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Significant improvements in functional status over time were observed in both the Early and Mid Trial groups ( Figure  3 ). More than 80% of patients tested in both groups improved to NYHA class I/II from NYHA class IIIB/IV by 6 months, and this was sustained through to 24 months. Six-minute walk distance for patients who could walk at baseline was 181Ϯ138 (ET, nϭ52) and 225Ϯ142 meters (MT, nϭ98), which improved to Ͼ340 m by 6 months and was sustained through 24 months in both groups.
Adverse Events
A comparison of adverse events between the 2 groups is shown in Table 2 . There were statistically significant reductions in adverse events between the Early and Mid Trial groups in bleeding requiring transfusions (1.66 versus 1.13 events per patient-year; risk ratio [RR]ϭ0.69, PϽ0.001), sepsis (0.38 versus 0.27, RRϭ0.70, Pϭ0.025), device related infections (0.47 versus 0.27 events per patient-year, RRϭ0.56, PϽ0.001), cardiac arrhythmias (0.69 versus 0.46, RRϭ0.67, Pϭ0.003), and hemorrhagic stroke (0.07 versus 0.03 events per patient-year, RRϭ0.40, Pϭ0.012). The rates of other adverse events including ischemic stroke, pump thrombosis, and pump replacements were similar between the 2 groups.
Causes of Death
Primary causes of death within the first 2 years of support are shown in Table 3 . Hemorrhagic stroke was the most common cause of death in the Early Trial group (8% [10/133]), which was significantly reduced to 2% (6/281) in the Mid Trial group (Pϭ0.012). Deaths caused by hemorrhagic stroke tended to occur sooner in the Early Trial group (231Ϯ180 days) compared with the Mid Trial group (351Ϯ225 days), although the difference was not statistically significant (Pϭ0.193). In the first 6 months of support, 5 patients (3.8%) died of hemorrhagic stroke in the Early Trial, which was significantly reduced to 1 patient (0.3%) in the Mid Trial (Pϭ0.014). However, there was no difference in the temporal occurrence of hemorrhagic stroke adverse events themselves (509Ϯ419 days [Early Trial] versus 469Ϯ468 days [Mid Trial], Pϭ0.810). There were no differences in other causes of death between the 2 groups including right heart failure (4% versus 4%, Pϭ1.00), bleeding (3% versus 4%, Pϭ1.00], sepsis (4% versus 3%, Pϭ0.764), ischemic stroke (1% versus 3%, Pϭ0.178), or multisystem organ failure (2% versus 2%, Pϭ1.00) for Early Trial versus Mid Trial groups, respectively. Figure 4 shows the proportion of patients receiving heparin in the immediate postoperative period in transition to long-term warfarin therapy. There were significant differences between the 2 groups in the proportion of patients receiving therapeutic, subtherapeutic, and no heparin postoperatively as a transition to warfarin therapy (Pϭ0.004). A larger proportion of patients did not receive heparin in the Mid Trial group Other causes of death include air embolism, anoxic brain injury, traumatic brain injury, cardiac arrest, cardiac failure, heart failure, respiratory failure, pneumonia, amyloidosis, cancer, liver failure, pancreatitis, withdrawal of support, respiratory failure, ruptured bladder, subdural hematoma, and unknown.
Anticoagulation Management
MOF indicates multiple organ failure. 
Discussion
This study demonstrates that outcomes in advanced heart failure patients treated with a continuous-flow LVAD (HMII) as destination therapy have continued to improve during the course of the clinical trial. Importantly, there were statistically significant reductions in serious adverse events including the incidence of hemorrhagic strokes, bleeding, driveline infection, and sepsis. Survival rates are now 73% at 1 year and 63% at 2 years. The 50% reduction in the incidence of hemorrhagic strokes directly had an impact on mortality, with hemorrhagic strokes being the cause of death in only 2% of mid trial patients as opposed to 8% in the early part of the trial. Improvements in outcomes are expected with increasing clinical experience with any new surgical therapy. However, in the case of the pulsatile HeartMate XVE LVAS, there was no improvement in survival between the original REMATCH study 15 and the most recent randomized DT trial 2 (1-year survival: 52% versus 55%), due to the limited durability of the device. Conversely, there has been a consistent improvement in outcomes in the HeartMate II BTT experience, with an increase in 1-year survival from 68% 6 to 73% 7 during the trial and 85% 8 in the post-trial experience. Some of these improvements observed can be attributed to better patient selection for the therapy, whereas others are possibly due to improved patient treatment before and after LVAD implant. These observations have resulted in an update of management guidelines for the HMII. 16 In the current study, most improvements are probably due to better postoperative and postdischarge patient treatment because the characteristics of patients selected were similar between the 2 cohorts, and the survival rates were similar for the first 60 days before showing a trend for improvement.
Reduction in hemorrhagic strokes and bleeding events could partly be attributed to improved anticoagulation regimen tailored specifically to the HMII. Initial recommendation for the HMII involved heparin in the immediate postoperative period, followed by warfarin with a target INR of 2.0 -3.0, aspirin (81-100 mg daily), and dipyridamole. Target INR range for warfarin therapy has now been reduced to 1.5-2.5, based on recent clinical findings reported by Boyle et al. 17 Additionally, patients with a HMII have been reported to have increased bleeding caused by acquired von Willebrand syndrome, which reduces platelet binding and activity. 18, 19 Also, recent clinical experiences have shown that heparin may not be needed in transition to warfarin in the postoperative period. 20 Slaughter et al 20 demonstrated that there was no difference in thrombotic events between patients who were transitioned to warfarin on heparin and those who were not transitioned. Furthermore, patients who were not on heparin had fewer bleeding events.
Changes in recommendations of anticoagulation management have been highlighted in the updated patient treatment guidelines for HMII. 16 Results in the current study also indicate a general trend as the trial progressed of less use of heparin for bridging to warfarin along with a lower target INR, a trend that was most evident in the first 6 months of the early part of the trial (Figures 4 and 5) . With respect to antiplatelet medications, there were not enough data in the trial to make any conclusions on their impact on bleeding and hemorrhagic strokes. Changes to the anticoagulation strategy could be one of the contributing factors leading to an overall reduction in bleeding and hemorrhagic stroke events in the Mid Trial group.
Introduction of the HMII and smaller-sized continuousflow LVADs have significantly reduced the incidence of driveline infections and sepsis from the pulsatile LVADs. 2 However, infection continues to be a significant source of morbidity and one of the primary reasons for prolonged hospital length of stay 21 and hospital readmissions. As more patients are on mechanical circulatory support for longer periods of time, there is an increasing need for reducing driveline infections. Our study has shown an additional reduction in driveline infection, localized non-device-related infection, and sepsis event rates in the mid trial period. The finding indicates that both clinicians and patients have learned from the early trial experience and were more cognizant about the importance of stabilization of the driveline, management of the driveline exit site, and overall patient treatment, which eventually resulted in lower infection rates. From the results of this updated study in 281 DT patients, we can infer a magnitude of the survival benefit of continuous-flow LVAD compared with the medical arm of REMATCH representing optimal medical management for 2001, which is shown in Figure 6 .
Conclusions
The benefit of DT therapy with the HMII is confirmed in subsequent trial patients. The survival rates in these patients are now 73% at 1 year and 63% at 2 years. These were substantial reductions in serious adverse events including hemorrhagic strokes (Ͼ50% reduction), localized nondevice-related infection (35% reduction), sepsis (30% reduction), device-related infections (Ͼ40% reduction), bleeding requiring transfusion (Ͼ30% reductions), and cardiac arrhythmias (Ͼ30% reduction). There were also fewer deaths due to hemorrhagic strokes. These improvements highlight that both clinicians and patients are benefiting from the increasing clinical experience associated with the use of HMII for long-term treatment of advanced heart failure, which are directly getting translated to improving clinical outcomes. 
Disclosures
